UK Companies House feature
BRAIN TUMOUR RESEARCH
Cash
—
Latest balance sheet
Net assets
£1
0% vs 2020
Employees
—
Average over period
Profit before tax
—
Period ending 2021-06-30
Profile
- Company number
- 08570737
- Status
- Active
- Incorporation
- 2013-06-14
- Last accounts made up
- 2024-06-30
- Account category
- FULL
- Primary SIC
- 86900
- Hubs
- UK Healthcare
Net assets
2-year trend · vs UK Healthcare median
Accounts
2-year trend · latest 2021-06-30
| Metric | Trend | 2020-06-30 | 2021-06-30 |
|---|---|---|---|
| Turnover | — | — | |
| Operating profit | — | — | |
| Profit before tax | — | — | |
| Net profit | — | — | |
| Cash | — | — | |
| Total assets less current liabilities | — | — | |
| Net assets | £1 | £1 | |
| Equity | £1 | £1 | |
| Average employees | — | — | |
| Wages | — | — |
Values shown as filed in iXBRL accounts. — indicates the figure was not present in the extracted filing (either not filed under that concept or absent from the period). About these numbers
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Moore Kingston Smith LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Management and the Trustees regularly review detailed forecasts of income, expenditure and cash flows, regularly projecting forward 12 months or more. The Trustees are, therefore, satisfied that the financial statements should be prepared on the going concern basis and have advised Management to work on the basis of a continued growth strategy with initiatives and contingencies built in.”
Significant events
- “September 2024 - £500,000 funding boost for paediatric research at our Centre of Excellence at the Institute of Cancer Research.”
- “October 2024 - Blocking MERTK protein shown to halt growth of meningioma and schwannoma tumour cells.”
- “January 2025 - Launch of the Scottish Brain Tumour Research Centre of Excellence, dedicated to advancing treatments for glioblastoma.”
- “February 2025 - Announcement of a new trial to predict effective treatment options for glioblastoma.”
- “February 2025 - Brain Tumour Research helps shape the Rare Cancers Bill.”
- “March 2025 - £2.5 million awarded to our Centre of Excellence at Queen Mary University of London.”
- “March 2025 - Celebrated our 15th anniversary with the publication of Closer to a Cure – 15 Years of Impact.”
- “May 2025 - Dr Sarah Kingdon awarded Scotland's first dedicated Neuro-oncology Fellowship.”
- “May 2025 - Innovative new technique developed to study recurrent glioblastoma.”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
11 active · 9 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| ARON, Jeremy Andrew | Director | 2017-06-06 | Aug 1964 | British |
| BOUTWOOD, Nigel Peter Ralph | Director | 2013-06-14 | May 1951 | British |
| FULCHER, Wendy Dianne | Director | 2013-06-14 | Sep 1951 | British |
| GOODWIN, Jack Andrew | Director | 2023-08-01 | Sep 1987 | British |
| HAINES, Nicola Elizabeth, Dr | Director | 2023-11-01 | Mar 1976 | British |
| HORROCKS, Sonia Ali | Director | 2025-10-09 | Apr 1992 | British |
| HUGHES, Robert | Director | 2013-06-14 | Sep 1956 | British |
| JARRETT, Melanie | Director | 2024-11-08 | Dec 1964 | British |
| KIRBY-HOGARTY, Oscar | Director | 2025-10-09 | Aug 1992 | British |
| SAUNDERS, David Michael | Director | 2013-06-14 | Jun 1935 | British |
| SEFTON, Denise Elaine | Director | 2023-08-01 | Jun 1975 | British |
Show 9 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| DAWE, Nicholas David | Director | 2020-10-05 | 2022-05-05 |
| FARRINGTON SMITH, Susan Mary | Director | 2023-07-01 | 2025-07-31 |
| GHOSH, Sukanta | Director | 2021-01-27 | 2024-06-30 |
| KELLY, Gerard William | Director | 2017-06-06 | 2020-10-08 |
| MCKAY, Stuart | Director | 2013-06-14 | 2020-05-21 |
| PAINTER, Stephen John | Director | 2015-10-22 | 2018-10-15 |
| RANFT, Jessica Anne | Director | 2017-06-06 | 2023-02-09 |
| ROBERTSON, Carol | Director | 2013-06-14 | 2013-11-01 |
| STOCKHAM TURNER, Margaret Jean, Dr | Director | 2017-06-06 | 2023-07-31 |
Ownership
Persons with significant control
Filing timeline
Last 20 of 61 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2026-05-05 | AA | accounts | accounts with accounts type full |
| 2025-10-21 | AP01 | officers | appoint person director company with name date |
| 2025-10-21 | AP01 | officers | appoint person director company with name date |
| 2025-08-04 | TM01 | officers | termination director company with name termination date |
| 2025-06-13 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2024-12-27 | AA | accounts | accounts with accounts type full |
| 2024-11-18 | AP01 | officers | appoint person director company with name date |
| 2024-07-01 | TM01 | officers | termination director company with name termination date |
| 2024-06-17 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2024-03-28 | AA | accounts | accounts with accounts type full |
| 2023-11-07 | CH01 | officers | change person director company with change date |
| 2023-11-06 | AP01 | officers | appoint person director company with name date |
| 2023-08-02 | AP01 | officers | appoint person director company with name date |
| 2023-08-01 | AP01 | officers | appoint person director company with name date |
| 2023-08-01 | TM01 | officers | termination director company with name termination date |
| 2023-07-04 | AP01 | officers | appoint person director company with name date |
| 2023-06-15 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2023-03-31 | AA | accounts | accounts with accounts type full |
| 2023-02-25 | TM01 | officers | termination director company with name termination date |
| 2022-06-23 | CS01 | confirmation-statement | confirmation statement with no updates |
Credit score
Altman Z″ — composite of working capital, retained earnings, EBIT, and leverage
Activity Score
Filings velocity, capital events, officer churn, accounts trajectory